RFK Jr. challenges a Democratic senator’s claim that a 600% drug price drop is impossible by pointing out that if a price goes from $600 down to $100, that’s technically a 600% savings from the higher price. Trump chimes in with agreement.

• RFK Jr. claimed a drop from $600 to $100 equals a "600% savings," which is mathematically wrong (it's actually a 500/6 ≈ 83% decrease).
• Trump agreed with RFK Jr.'s flawed math in real time, saying "Right."
• The exchange was used by a reporter to illustrate how the administration frames drug pricing with misleading statistics.

Americans spend more on healthcare than any other country, largely because the U.S. pays far higher prices for the same surgeries, drugs and medical services. Increased use of costly hospital care and new weight-loss medications has driven spending even higher.

• U.S. families pay about $27,000 a year on average for health insurance.
• Identical procedures (hip replacements, MRIs) and even generic drugs cost far more in the U.S. than in other countries.
• Rising hospital utilization is pushing spending higher.
• New weight-loss drugs, costing thousands per month, are a significant driver of increased healthcare spending.

TrumpRx, a new public-private program launched by the Trump administration in partnership with Pfizer, aims to offer direct-to-consumer drug sales at significantly reduced prices. While it seeks to provide discounts on medications, experts suggest it closely resembles existing DTC models like Cost Plus Drugs and may not substantially impact the majority of patients who rely on insurance for prescriptions.

• TrumpRx is a new public-private drug pricing program launched by the Trump administration with Pfizer offering direct-to-consumer sales at reduced prices.
• Experts say it closely resembles existing DTC models like Mark Cuban's Cost Plus Drugs rather than being a novel approach.
• Since most patients rely on insurance rather than paying cash for prescriptions, the program likely won't have a major impact on the majority of drug purchasers.